Milan 2012 Programme Registration Exhibition Hotels Exhibitor Listing Satellite Meetings Visa Information
Search Abstracts by author or title
(results will display both Free Papers & Poster)

Intracor: stable solution for presbyopia

Poster Details

First Author: N.Gabric CROATIA

Co Author(s):    I. Dekaris   M. Bohac           

Abstract Details



Purpose:

To evaluate stability and safety in outcome of Intracor procedure for treatment of presbyopia.

Setting:

University Eye Hospital Svjetlost, Zagreb, Croatia

Methods:

Ongoing prospective study on patients who underwent Intracor procedure in the University Eye Hospital Svjetlost since December 2010. 265 patients underwent procedure (41 bilateral and 183 unilateral) with 100 patients having follow up of more than six months. Follow up consisted of uncorrected and corrected distant and near visual acuity, evaluation of topographic changes, and standardized questionnaire about patient visual disturbances and satisfaction.

Results:

Mean equivalent (ME) of uncorrected distant visual acuity was 0,8 ±0,2 and ME of near uncorrected visual acuity was J2. Difference maps (Tue Net Power) taken from Pentacam HR (Oculus) showed variation in central corneal curvature increase ranging from 0.1 to 2.5D with no decrease in central corneal curvature throughout a 6 months period of follow up. There could not be made any clinical correlation between the central corneal curvature increase and patients overall near and distant visual acuity improvement. Visual and refractive results stabilized over a one month period and remained stable during the whole follow up period. Patients with bilateral treatment demonstrated better near and distant vision performances than patients with monocular treatment. 93% of patients were satisfied with their visual performances in distance, intermediate and near vision. Only eleven patients reported mild halo and glare.

Conclusions:

Intracor procedure has proven its short term stability, safety and efficacy in treating presbyopia. However, longer follow up period is needed. FINANCIAL DISCLOSURE?: No

Back to previous

loading Please wait while information is loading.